Low-dose naltrexone for long COVID is one of the most discussed off-label topics in long COVID communities, and it is being studied in early clinical research. This article reports what patients and researchers are actually talking about in 2026 and what you might track over time. It is informational only. It is not medical advice, not a recommendation, and not a claim that low-dose naltrexone works. Any decision about it belongs with your own doctor.
Key takeaways
- Low-dose naltrexone (often written as LDN) is naltrexone used off-label at much smaller doses than its approved uses. It is widely discussed in long COVID and ME/CFS communities.
- Evidence in long COVID is early and limited. This post reports the conversation and the research interest, not proven benefit.
- We give no dosing guidance and make no efficacy claims. Whether LDN is appropriate for you is a question for a licensed clinician.
- Because it is framed as an anti-inflammatory intervention, some people want objective markers to watch alongside their symptoms, such as IL-6, TNF, and CRP.
- Muno measures inflammation markers and benchmarks them against a healthy reference, so you can see how they change if you retest, for research and informational use with your doctor. It does not evaluate or approve any treatment.
What is low-dose naltrexone and why do long COVID patients discuss it?
Naltrexone is an approved medication for specific conditions at standard doses. Low-dose naltrexone refers to its off-label use at a fraction of those doses. In long COVID and ME/CFS forums, including long threads on Reddit, people discuss it because it is proposed to have anti-inflammatory and immune-modulating effects, and because standard care has left many of them without options. That is a description of a community conversation, not an endorsement.
Worth stating plainly: interest in a treatment is not proof it works. Off-label use means a drug is being used outside its approved indications, and that decision requires a clinician who knows your history. Nothing here should be read as a suggestion to start, stop, or change any medication.
What does the research on low dose naltrexone for long COVID say?
As of 2026 the evidence base is early. Low-dose naltrexone has been studied in a handful of small trials and observational reports in long COVID cohorts across post-viral and chronic-pain conditions, and it is being investigated in long COVID specifically, including within larger research efforts cataloguing candidate therapies. These studies are ongoing or limited in size, and they have not established that it is effective for long COVID. For a broader view of the pipeline, see how to tell whether a treatment is actually working.
The responsible summary is short. Researchers find it interesting enough to study. That interest is not the same as a proven result, and it does not tell any individual whether it will help them.
If someone tries an intervention, what can they track over time?
This is where objective measurement becomes useful, and it applies to any intervention, not just this one. Symptoms are real but hard to compare month to month, especially when fatigue and brain fog blur memory. Watching a set of markers alongside how you feel gives you a second, quantitative record.
Because low-dose naltrexone is discussed as an anti-inflammatory approach, the inflammation markers people most often want to monitor include:
- IL-6: a central inflammatory signaling cytokine.
- TNF: a core cytokine in sustained inflammatory signaling.
- CRP: a general marker of inflammation many people already recognize from routine labs.
Tracking these does not tell you whether a specific drug caused a change, and it is not a substitute for clinical judgment. A marker can move for many reasons. What a before-and-after record does is give you and your doctor concrete numbers to look at together, instead of memory alone. We walk through this approach in whether your long COVID recovery is actually working.
How would you measure inflammation markers before and after a change?
The idea is simple: establish a baseline, then retest after enough time has passed, and compare. Muno Mirror measures a broad panel of inflammation proteins, including IL-6, TNF, and CRP, from an at-home microsample, and benchmarks each one against a healthy reference range. Retesting later shows what moved. You can see the full set of markers Muno Mirror measures before deciding whether it fits.
Two boundaries stay fixed. Muno measures and benchmarks for research and informational purposes; it does not diagnose long COVID, and it does not evaluate, approve, or recommend low-dose naltrexone or any treatment. And the results are meant to be brought to your own doctor, who is the right person to interpret them in the context of your care. Muno's tests are laboratory-developed and have not been reviewed by the FDA.
Frequently asked questions
Does low-dose naltrexone work for long COVID?
We cannot say, and no one should tell you it does. The evidence in long COVID is early and limited, and studies have not established effectiveness. Low-dose naltrexone is discussed by patients and studied by researchers, but interest is not proof. Whether it is appropriate for you is a decision for a licensed clinician.
What dose of LDN do people use?
This article gives no dosing information on purpose. Dosing, timing, and suitability are medical decisions that depend on your history and other medications, and they must come from a doctor or pharmacist. Community posts are not a safe source of dosing guidance.
What markers can I track if I try an intervention with my doctor?
People monitoring inflammation often watch IL-6, TNF, and CRP over time, alongside their symptoms. Tracking these does not prove that any specific treatment caused a change, and many factors can move a marker. It gives you and your doctor objective numbers to compare across a baseline and a later retest.
Can Muno tell me whether low-dose naltrexone is helping me?
No. Muno measures inflammation markers and shows how they change if you retest, benchmarked against a healthy reference. It does not evaluate treatments or attribute changes to any drug. The results are informational, for you to review with your own doctor, who can interpret them within your overall care.